Revolutionizing Parkinson’s care: From a clinic-controlled to a patient-centric care model
Due to increasing life expectancy, Parkinson’s disease is now the fastest-growing neurological disorder globally, affecting individuals across all cultures and ethnicities. An estimated 10 million people currently live with the disease worldwide, a number projected to rise to 25 million by 2050.
Parkinson’s disease is a progressive neurodegenerative disorder caused by the loss of dopamine-producing neurons in the brain regions responsible for movement. Although there is currently no cure for Parkinson’s disease, a range of treatments is available to manage symptoms, enhance quality of life, and slow disease progression.
The disease is incredibly difficult to manage, with symptoms fluctuating throughout the day and even within a short period of time. This not only presents a significant burden to patients but also poses a complex challenge to clinicians, especially in planning highly personalized treatment and assessing treatment efficacy.
Effective management of Parkinson’s requires a comprehensive understanding of the patient’s symptoms over time. However, accurate and objective long-term data – particularly in home environments – is often lacking. Treatment planning is typically based on subjective observation and examination of patients during short clinic appointments and patient self-reporting, which may not fully capture the complexity of the symptoms.
Real-world symptom data is the basis for next-generation Parkinson’s care
At Adamant Health, we have developed the first research-based precision technology to measure the motor symptoms of Parkinson's disease. By combining surface electromyography (EMG) and kinematic measurement, we add the measurement of neuromuscular signals to motion measurement for deeper insight into muscle activity. With EMG and kinematic measurement, it is also possible to detect emerging, not yet physically visible symptoms and measure rigidity, which is not possible with any other technology.
We rely on the combination of two proven technologies – EMG and kinematic measurement – for unparalleled accuracy in symptom assessment and provide clinically meaningful and actionable data for therapeutic decision-making and treatment planning. This enables evidence-based decisions that lead to more effective symptom management.
Our measurement and analysis service complements clinical assessment and helps clinicians get a more holistic view of a patient’s condition by collecting symptom data over an extended period of time and at home.
Paradigm shift to patient-centric care
With the help of real-world data from the patient's life and modern AI technology, we will not only be able to optimize treatment and detect symptoms earlier but also transition from a clinic-controlled to a patient-centric care model.
Already today, we can provide clinically meaningful and actionable data to transform the current gold standard in Parkinson’s care into fact-based treatment optimization, enabling personalized and remote care.
By providing clinically validated, longitudinal, and multidimensional real-world data, we will enable a paradigm shift to a patient-centric care model, ultimately leading to real-time care optimization.
Within the patient-centric care model, patients will be empowered to take an active role in their care. They will be involved in the care process with clear insights into their health condition, helping them overcome feelings of helplessness and frustration, and preventing treatment fatigue. Automated treatment optimization will lead to an optimal care balance, with the clinic taking a supervisory role in monitoring the patient’s condition and intervening as needed.
The next-generation Parkinson’s care will impact every stage of the care pathway to achieve an optimal care balance for the patient, including maximum symptom control. This will enable people with Parkinson’s disease to live full and independent lives and simultaneously reduce the burden on the healthcare system.